Skip to content
Screener

Sionna Therapeutics SION Current ratio

Current ratio at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
3.2×+0.7×
AbbVie logo
AbbVieABBV
0.8×0.0×
Achieve Life Sciences logo
Achieve Life SciencesACHV
2.6×-0.9×
Septerna, Inc. logo
Septerna, Inc.SEPN
5×-17.1×
RFL
Rafael Holdings, Inc.RFL
3.2×-0.7×
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
9.3×-3.0×

Other financials

Income statement

See full
Operating income-$29.6M-50.6%
Net income-$26.8M-62.5%
EPS (diluted)-$0.60+3.2%

Balance sheet

See full
Cash & equivalents$64.3M-23.2%
Total debt$8.4M-11.8%
Total equity$288.2M-18.1%
Total assets$305.0M-17.5%

Cash flow

See full
Operating cash flow-$21.8M-34.1%
CapEx--100%
Free cash flow-$21.8M-33.4%

Valuation

See full
Market cap$203.46M-77.0%
Enterprise value$147.55M-82.7%

Returns & leverage

See full
Return on equity-26.7%—
Debt / equity0×0.0×

Where this comes from

Calculated from Sionna Therapeutics’s reported figures.

total current assets/total current liabilities=22.6×

Based on the most recent quarter.

The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026. Open the filing →

Filed
May 12, 2026, 7:17 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033876

FAQ

What is Sionna Therapeutics's current ratio?
Sionna Therapeutics (SION) reported current ratio of 22.6× in Q1 2026.
How has Sionna Therapeutics's current ratio changed year-over-year?
Sionna Therapeutics's current ratio decreased by 21.3% year-over-year, from 28.7× to 22.6×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.

Ask your AI about Sionna Therapeutics's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude